Cargando…

Recombinant toxin-coregulated pilus A (TcpA) as a candidate subunit cholera vaccine

BACKGROUND AND OBJECTIVES: The toxin co-regulated pilus A (TcpA) has been described as a critical pathogenicity factor of Vibrio cholerae. TcpA is a candidate for making subunit vaccine against cholera. The aim of this study was to produce a candidate vaccine by expressing recombinant TcpA in E. col...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiaie, Somayeh, Abtahi, Hamid, Mosayebi, Ghasem, Alikhani, MohammadYosef, Pakzad, Iraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281662/
https://www.ncbi.nlm.nih.gov/pubmed/25705354
_version_ 1782351027814531072
author Kiaie, Somayeh
Abtahi, Hamid
Mosayebi, Ghasem
Alikhani, MohammadYosef
Pakzad, Iraj
author_facet Kiaie, Somayeh
Abtahi, Hamid
Mosayebi, Ghasem
Alikhani, MohammadYosef
Pakzad, Iraj
author_sort Kiaie, Somayeh
collection PubMed
description BACKGROUND AND OBJECTIVES: The toxin co-regulated pilus A (TcpA) has been described as a critical pathogenicity factor of Vibrio cholerae. TcpA is a candidate for making subunit vaccine against cholera. The aim of this study was to produce a candidate vaccine by expressing recombinant TcpA in E. coli. MATERIALS AND METHODS: In this study, the toxin co-regulated pilus A gene from EL-Tor, V. cholerae subspecies, was amplified by PCR and sub-cloned into prokaryotic expression vector pGEX4T1. E. coli BL21 (DE3) was transformed with pGEX4T1- TcpA and gene expression was induced by IPTG and purified by GST resin. The integrity of the product was confirmed by Western blot analysis using a standard rabbit anti-V. cholerae antibody. Sera reactivity of infected individuals was further analyzed against the recombinant TcpA protein. RESULTS: The concentration of purified recombinant protein was calculated to be 8 mg/L of initial culture. The integrity of product was confirmed by Western blot analysis using a standard rabbit anti V. cholerae antibody. Sera reactivity of infected individual was further analyzed against the recombinant TcpA protein. The obtained data indicated that recombinant TcpA protein from V. cholerae was recognized by patient serum and animal sera. CONCLUSION: These results show that the recombinant TcpA is antigenic and could be used in a carrier host as an oral vaccine against cholera.
format Online
Article
Text
id pubmed-4281662
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-42816622015-02-20 Recombinant toxin-coregulated pilus A (TcpA) as a candidate subunit cholera vaccine Kiaie, Somayeh Abtahi, Hamid Mosayebi, Ghasem Alikhani, MohammadYosef Pakzad, Iraj Iran J Microbiol Medical Sciences BACKGROUND AND OBJECTIVES: The toxin co-regulated pilus A (TcpA) has been described as a critical pathogenicity factor of Vibrio cholerae. TcpA is a candidate for making subunit vaccine against cholera. The aim of this study was to produce a candidate vaccine by expressing recombinant TcpA in E. coli. MATERIALS AND METHODS: In this study, the toxin co-regulated pilus A gene from EL-Tor, V. cholerae subspecies, was amplified by PCR and sub-cloned into prokaryotic expression vector pGEX4T1. E. coli BL21 (DE3) was transformed with pGEX4T1- TcpA and gene expression was induced by IPTG and purified by GST resin. The integrity of the product was confirmed by Western blot analysis using a standard rabbit anti-V. cholerae antibody. Sera reactivity of infected individuals was further analyzed against the recombinant TcpA protein. RESULTS: The concentration of purified recombinant protein was calculated to be 8 mg/L of initial culture. The integrity of product was confirmed by Western blot analysis using a standard rabbit anti V. cholerae antibody. Sera reactivity of infected individual was further analyzed against the recombinant TcpA protein. The obtained data indicated that recombinant TcpA protein from V. cholerae was recognized by patient serum and animal sera. CONCLUSION: These results show that the recombinant TcpA is antigenic and could be used in a carrier host as an oral vaccine against cholera. Tehran University of Medical Sciences 2014-04 /pmc/articles/PMC4281662/ /pubmed/25705354 Text en Copyright © Iranian Journal of Microbiology & Tehran University of Medical Sciences This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Medical Sciences
Kiaie, Somayeh
Abtahi, Hamid
Mosayebi, Ghasem
Alikhani, MohammadYosef
Pakzad, Iraj
Recombinant toxin-coregulated pilus A (TcpA) as a candidate subunit cholera vaccine
title Recombinant toxin-coregulated pilus A (TcpA) as a candidate subunit cholera vaccine
title_full Recombinant toxin-coregulated pilus A (TcpA) as a candidate subunit cholera vaccine
title_fullStr Recombinant toxin-coregulated pilus A (TcpA) as a candidate subunit cholera vaccine
title_full_unstemmed Recombinant toxin-coregulated pilus A (TcpA) as a candidate subunit cholera vaccine
title_short Recombinant toxin-coregulated pilus A (TcpA) as a candidate subunit cholera vaccine
title_sort recombinant toxin-coregulated pilus a (tcpa) as a candidate subunit cholera vaccine
topic Medical Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281662/
https://www.ncbi.nlm.nih.gov/pubmed/25705354
work_keys_str_mv AT kiaiesomayeh recombinanttoxincoregulatedpilusatcpaasacandidatesubunitcholeravaccine
AT abtahihamid recombinanttoxincoregulatedpilusatcpaasacandidatesubunitcholeravaccine
AT mosayebighasem recombinanttoxincoregulatedpilusatcpaasacandidatesubunitcholeravaccine
AT alikhanimohammadyosef recombinanttoxincoregulatedpilusatcpaasacandidatesubunitcholeravaccine
AT pakzadiraj recombinanttoxincoregulatedpilusatcpaasacandidatesubunitcholeravaccine